Tiffany earned her PhD in Genetics from North Carolina State University, where she explored the effect of genetic background on the ability to derive induced pluripotent stem cells. She completed her postdoctoral training at the University of North Carolina at Chapel Hill, specializing in the development of translational approaches to direct cardiac reprogramming and understanding the mechanisms of cardiomyocyte maturation. She has written for multiple medical, nonprofit, and academic peer-reviewed outlets. In March 2020, Tiffany joined LabX Media Group as an assistant science editor for The Scientist. She began working with Drug Discovery News in October 2020.
Bats, pigs, and pangolins – oh my! The COVID-19 pandemic highlighted the consequences of viral spillover from animals, but it is not the first time in history that an animal virus has spurred disease in humans.
A naturally occurring nanoparticle yields a new type of vaccine that offers broad-acting protection against emerging SARS-CoV-2 variants. With further development, the approach may lead to a pan-coronavirus vaccine.
Single-nucleotide polymorphisms (SNPs) occur where a single base pair at a specific locus differs from the standard sequence. The SNP might relate to disease susceptibility, pathogenesis of disease, or efficacy of specific drugs. Identifying SNPs is useful for improving our understanding of human genetics and as a clinical diagnostic tool.